CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED ASSET PURCHASE AND REDEMPTION AGREEMENTAsset Purchase and Redemption Agreement • February 28th, 2023 • Landos Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase and Redemption Agreement (this “Agreement”) dated as of February 28, 2023 between Landos Biopharma, Inc. (“Landos” or “Seller”), a corporation organized under the laws of the State of Delaware, Dr. Josep Bassaganya-Riera (“JBR” or “Agent”), on his own behalf and on behalf of the persons listed on Schedule A annexed hereto and made a part hereof (the “Selling Entities”), Raquel Hontecillas (together with JBR and the Selling Entities, the “Stockholders”), and each of the Selling Entities. Landos, Agent and the Stockholders are referred to herein collectively as the “Parties” and each individually as a “Party”.
